Colistin is NOT Appropriate for Burkholderia cepacia Complex Infections
Colistin (polymyxin E) should not be used to treat Burkholderia cepacia complex (Bcc) infections due to intrinsic resistance—these organisms are naturally resistant to polymyxins and clinical data consistently demonstrate treatment failure with colistin. 1, 2, 3
Intrinsic Resistance Mechanism
- Bcc possesses modified lipopolysaccharide (LPS) in its outer membrane that confers intrinsic polymyxin resistance, making colistin ineffective regardless of in vitro susceptibility testing results 3
- Multiple outbreak investigations have documented universal resistance to polymyxin B and colistin among Bcc isolates 2
- The outer membrane penetration barrier serves as the first line of defense against antimicrobials in Burkholderia species, with polymyxins being particularly affected 3
Clinical Evidence Against Colistin Use
- In a documented outbreak of 29 Bcc-positive blood cultures, all isolates showed resistance to polymyxin B and colistin, while showing sensitivity to other agents 2
- A tertiary hospital report analyzing 38 Bcc infections found colistin sensitivity in 93% by standard testing, yet this did not reflect the intrinsic resistance mechanisms that limit clinical efficacy 4
- Critical caveat: Standard disc diffusion and automated susceptibility testing methods are poorly reproducible for Bcc and do not accurately predict clinical outcomes 1, 5
Recommended Alternative Antibiotics
Based on demonstrated in vitro activity and clinical outcomes, use these agents instead:
First-Line Options:
- Trimethoprim-sulfamethoxazole (cotrimoxazole): Most consistently active agent with 71% sensitivity in clinical series 1, 4
- Meropenem or doripenem: Carbapenems show good activity against Bcc 1
- Ceftazidime: Third-generation cephalosporin with documented efficacy, though resistance via β-lactamases is emerging 1, 3
Second-Line Options:
- Minocycline or doxycycline: Tetracyclines demonstrate activity 1
- Piperacillin-tazobactam or cefoperazone-sulbactam: β-lactam/β-lactamase inhibitor combinations showed universal sensitivity in outbreak data 2
- Fluoroquinolones (levofloxacin): Variable activity, use based on susceptibility testing 1, 2
Critical Diagnostic Considerations
- Species identification is essential: Phenotypic methods lack sensitivity; molecular testing (PCR-based methods) is required for accurate Bcc identification 1, 2
- Broth microdilution, agar dilution, or Etest are superior to disc diffusion for susceptibility testing 1
- Recent guideline changes (CLSI 2025, EUCAST 2024) have withdrawn breakpoints for most agents against Bcc, requiring MIC reporting based on wild-type/non-wild-type distributions 6
- Standard susceptibility testing in Mueller-Hinton broth poorly predicts clinical outcomes; activity in artificial sputum medium shows major discrepancies 5
Special Population: Cystic Fibrosis Patients
- Bcc infections in CF patients are particularly challenging, with Burkholderia cenocepacia infection being an exclusion criterion for lung transplantation 7
- These infections can progress to necrotizing pneumonia with bacteremia and fatal outcomes 7
- The absence of standardized therapeutic schemes and poor correlation between antibiograms and clinical results necessitates treatment based on documented active agents, explicitly excluding polymyxins 7
Why Guidelines Don't Address Bcc-Colistin Specifically
The major antimicrobial resistance guidelines 8, 9 focus on carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Pseudomonas aeruginosa (CRPA), and carbapenem-resistant Acinetobacter baumannii (CRAB)—organisms where polymyxins retain activity. Bcc is fundamentally different due to its intrinsic polymyxin resistance mechanism and is not included in carbapenem-resistant Gram-negative bacilli (CRGNB) treatment algorithms that recommend polymyxins 8, 9.